Conference
Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP).
Authors
McKenzie MR; Chi KN; Neville A; Ellard S; Baerg B; Ruether D; Winquist E; Segal R; Lukka H
Volume
24
Pagination
pp. 249S-249S
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
June 20, 2006
Name of conference
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Conference place
Atlanta, GA
Conference start date
June 2, 2006
Conference end date
June 6, 2006
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
18
ISSN
0732-183X